![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients ... Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys. Show more
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM:...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, June 17, 2024 STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed...
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire STOCKHOLM, May 30, 2024 STOCKHOLM, May 30, 2024...
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire STOCKHOLM, May 30, 2024 STOCKHOLM, May 30, 2024...
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress PR Newswire STOCKHOLM, May 28, 2024 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB...
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress PR Newswire STOCKHOLM, May 28, 2024 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions